RX 10001

Drug Profile

RX 10001

Alternative Names: Resolvin E1; RvE-1; RX-10001

Latest Information Update: 04 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Resolvyx Pharmaceuticals
  • Class Antiasthmatics; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cardiovascular disorders; Corneal disorders; Dry eyes; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 04 May 2016 Discontinued - Phase-I for Asthma (In volunteers) in USA (PO)
  • 04 May 2016 Discontinued - Phase-I for Cardiovascular disorders in USA (PO)
  • 04 May 2016 Discontinued - Phase-I for Inflammatory bowel disease (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top